BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients

Cancer Investigation

Volumn 32, Issue 8, 2014, Pages 375-387

  Cecener, Gulsah ^a   Egeli, Unal ^a   Tunca, Berrin ^a   Erturk, Elif ^a   Ak, Secil ^a   Gokgoz, Sehsuvar ^a   Tasdelen, Ismet ^a   Tezcan, Gulcin ^a   Demirdogen, Elif ^a   Bayram, Nuran ^a   Avci, Nilufer ^a   Evrensel, Turkkan ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

A GVGD; BRCA1 BRCA2 gene; BRCAPRO; Breast cancer; HSF

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; FOLLOW UP; FRAMESHIFT MUTATION; GENETIC RISK; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MISSENSE MUTATION; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; TURK (PEOPLE); AGED; BREAST TUMOR; GENETIC POLYMORPHISM; GENETICS; TURKEY; YOUNG ADULT;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC VARIATION; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; TURKEY; YOUNG ADULT;

EID: 84906225413     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2014.919302     Document Type: Article

References (61)

1. Downs-Holmes C, Silverman P. Breast cancer: overview and updates. The Nurse Practitioner 2011;12:20-26.
2. Key TJ, Verkasalo PK. Banks E epidemiology of breast cancer. Lancet Oncol 2001;2:133-140.
3. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute, 2011.
4. Ozmen V, Ozcinar B, Karanlik H. Breast cancer risk factors in Turkish women-a University Hospital based nested case control study.World J Surg Oncol 2009;8:7-37.
5. Kim Y, Choi JY, Lee KM, Park SK, Ahn SH, Noh DY, Hong YC, Kang D, Yoo KY. Dose dependent protective effect of breast feeding against breast cancer among ever lactated women in Korea. Eur J Cancer Prev 2007;16:124-129.
6. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
7. Tuncer M. Significance of cancer in Turkey, the burden of disease and cancer control policies. Health Ministry Pub 2008;74:5-9.
8. Egeli U, Cecener G, Tunca B, Tasdelen I. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives. Cancer Invest 2006;24: 484-491.
9. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997;60:1013-1020.
10. Ferla R, Calò V. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 2007;6:93-98.
11. AbeliovichD,KaduriL,Lerer I,WeinbergN, AmirG, SagiM, Zlotogora J, Heching N, Peretz T. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505-514.
12. Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, Shohat M, Weber BL, Beller U, Lahad A, Halle D. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997;60:1059-1067.
13. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200.
14. Robles-Diaz L, Goldfrank DJ, Kauff ND, Robson M, Offit K. Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer 2004;3:259-264.
15. Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, Lee MK, Goode EL, Rowell SE, King MC. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 1995;57:1284-1297.
16. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-187.
17. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, Hampel H, Borgen P, Brown K, SkolnickM, Shattuck-Eidens D, Jhanwar S, Goldgar D, Offit K. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13:126-128.
18. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjörd JE. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996;13:117-119.
19. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, Johannsson OT, Borg A, Ingvarsson S, Easton DF, Egilsson V, Barkardottir RB.High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996;56:3663-3665.
20. Bergthorsson JT, Jonasdottir A, Johannesdottir G, Arason A, EgilssonV,Gayther S, Borg A, Hakanson S, Ingvarsson S, Barkardottir RB. Identification of a novel splice-site mutation of the BRCA1 gene in two breast cancer families: screening reveals low frequency in Icelandic breast cancer patients. Hum Mutat 1998;1:195-197.
21. Rafnar T, Benediktsdottir KR, Eldon BJ, Gestsson T, Saemundsson H, Olafsson K, Salvarsdottir A, Steingrimsson E, Thorlacius S. BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. Eur J Cancer 2004;40:2788-2793.
22. Møller P, Heimdal K, Apold J, Fredriksen A, Borg A, Hovig E, Hagen A, Hagen B, Pedersen JC, Maehle L; Norwegian Inherited Breast Cancer Group; Norwegian Inherited Ovarian Cancer Group. Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer 2001;37:2428-2434.
23. Heimdal K, Maehle L, Apold J, Pedersen JC, Møller P. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Eur J Cancer 2003;39:2205-2213.
24. Rudkin TM, Hamel N, Galvez M, Hogervorst F, Gille JJ, Møller P,Apold J, FoulkesWD.The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations. BMC Med Genet 2006;1:7-15.
25. Reeves MD, Yawitch TM, van der Merwe NC, van den Berg HJ, Dreyer G, van Rensburg EJ. BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families. Int J Cancer 2004;110:677-682.
26. Vega A, Campos B, Bressac-De-Paillerets B, Bond PM, Janin N, Douglas FS, Domènech M, Baena M, Pericay C, Alonso C, Carracedo A, Baiget M, Diez O. The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat 2001;419:1-6.
27. Grzybowska E, Siemińska M, Zientek H, Kalinowska E, Michalska J, Utracka-Hutka B, Rogozińska-Szczepka J, Kázmierczak-Maciejewska M. Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population. Acta Biochim Pol 2002;49:351-356.
28. Pohlreich P, Zikan M, Stribrna J, Kleibl Z, Janatova M, Kotlas J, Zidovska J,Novotny J, Petruzelka L, Szabo C,Matous B.High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res 2005;7:728-736.
29. Cierniková S, TomkaM,Kovác M, Stevurková V, ZajacV.Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.Neoplasma 2006;53:97-102.
30. Gronwald J, Elsakov P, Górski B, Lubiński J. High incidence of 4153delA BRCA1 gene mutations in Lithuanian breast and breast-ovarian cancer families. Breast Cancer Res Treat 2005;94: 111-113.
31. Hamel N, Feng BJ, Foretova L, Stoppa-Lyonnet D, Narod SA, Imyanitov E, Sinilnikova O, Tihomirova L, Lubinski J, Gronwald J, Gorski B, Hansen Tv, Nielsen FC,Thomassen M, Yannoukakos D, Konstantopoulou I, Zajac V, Ciernikova S, Couch FJ, Greenwood CM, Goldgar DE, Foulkes WD. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 2011;19:300-306.
32. Laitman Y, Simeonov M, Herskovitz L, Kushnir A, Shimon-Paluch S, Kaufman B, Zidan J, Friedman E. Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel. Breast Cancer Res Treat 2012;133:1153-1157.
33. Balci A, Huusko P, Pääkkönen K, Launonen V, Uner A, Ekmekçi A,Winqvist R.Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3424del4 found in male breast cancer. Eur J Cancer 1999;35:707-710.
34. Ozdag H, Tez M, Sayek I, Muslumanoglu M, Tarcan O, Içli F, Oztürk M, Ozçelik T. Germline BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients. Eur J Cancer 2000;36:2076-2082.
35. Yazici H, Bitisik O, Akisik E, Cabioglu N, Saip P, Muslumanoglu M, Glendon G, Bengisu E, Ozbilen S, Dincer M, Turkmen S, Andrulis IL, Dalay N, Ozcelik H. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients. Br J Cancer 2000;83:737-742.
36. Manguoglu AE, Lüleci G, Ozçelik T, Colak T, Schayek H, AkaydinM, Friedman E.Germlinemutations in the BRCA1and BRCA2 genes in Turkish breast/ovarian cancer patients. Hum Mutat 2003;21:444-445.
37. YaziciH,GlendonG, Yazici H, Burnie SJ, SaipP,Buyru F, Bengisu E, Andrulis IL, Dalay N, Ozcelik H. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in nonfamilial cases. Hum Mutat 2002;20:28-34.
38. AktasD, GultekinM, KabacamS,AlikasifogluM,TuranAT,Tulunay G, KoseMF, Ortac F, Yüce K, Tunçbilek E, Ayhan A. Identification of point mutations and large rearrangements in the BRCA1 gene in 667 Turkish unselected ovarian cancer patients. Gynecol Oncol 2010;119:131-135.
39. Tavtigian SV,Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006;43:295-305.
40. Desmet FO, Hamroun D, LalandeM, Collod-Béroud G, Claustres M, Béroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucl Acids Res 2009;37:1-14.
41. Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, RubinsteinWS, Hughes KS, Parmigiani G. BRCAPRO validation. Sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002;20:2701-2712.
42. Chan PA, Duraisamy S, Miller PJ, Newell JA, McBride C, Bond JP, Raevaara T, Ollila S, Nyström M, Grimm AJ, Christodoulou J, OettingWS, Greenblatt MS. Interpreting missense variants: comparing computationalmethods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Hum Mutat 2007;28:683-693.
43. Thusberg J, Vihinen M. Pathogenic or not? And if so, then how? Studying the effects of missense mutations using bioinformatics methods. Hum Mutat 2009;30:703-714.
44. Tunca B, Pedroni M, Cecener G, Egeli U, Borsi E, Zorluoglu A, GregorioCD, YilmazlarT,Yerci O, and Ponz de LeonM.Analysis of mismatch repair gene mutations in Turkish HNPCC patients. Familial Cancer 2010;9:365-376.
45. Osorio A, Barroso A, Martínez B, Cebrián A, San Román JM, Lobo F, Robledo M, Benítez J. Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer 2000;82:1266-1270.
46. Goelen G, Teugels E, Bonduelle M, Neyns B, De Grève J. High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects. J Med Genet 1999;36:304-308.
47. Stuppia L, Di Fulvio P, Aceto G, Pintor S, Veschi S, Gatta V, Colosimo A, Cianchetti E, Cama A, Mariani-Costantini R, Battista P, Palka G. BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy. Hum Mutat 2003;22:178-179.
48. Meindl A. German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002;97:472-480.
49. Verhoog LC, Van den Ouweland AM, Berns E, Van Veghel-Plandsoen MM, Van Staveren IL,Wagner A, Bartels CC, Tilanus-Linthorst MM, Devilee P, Seynaeve C, Halley DJ, Niermeijer MF, Klijn JG, Meijers-Heijboer H. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer 2001; 16: 2082-2090.
50. Vehmanen P, Friedman LS, Eerola H,McClure M,Ward B, SarantausL, KainuT, Syrjäkoski K, Pyrhönen S,KallioniemiOP,Muhonen T, Luce M, Frank TS, Nevanlinna H. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 1997;13:2309-2315.
51. Ghaderi A, Talei A, Farjadian S, Mosalaei A, Doroudchi M, Kimura H. Germline BRCA1 mutations in Iranian women with breast cancer. Cancer Lett 2001;165:87-94.
52. Cecener G. Frame-Shift Mutations in BRCA1 and BRCA2 Genes inTurkishFamilieswithBreast and/orOvarianCancer, NewYork: Nova Biomedical Books, 2010.
53. Borg A, Haile RW, Malone KE, Capanu M, Diep A, Törngren T, Teraoka S, Begg CB, Thomas DC, Concannon P, Mellemkjaer L, Bernstein L, Tellhed L, Xue S, Olson ER, Liang X, Dolle J, Børresen-Dale AL, Bernstein JL. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the Wecare study. Hum Mutat Brief 2010;31:1200-1240.
54. Güran S, Ozet A, Dede M, Gille JJ, Yenen MC. Hereditary breast cancer syndromes in a Turkish population. Results of molecular germline analysis. Cancer Genet Cytogen 2005;160:164-168.
55. Cartegni L, Wang J, Zhu Z. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003;31: 3568-3571.
56. Sironi M, Menozzi G, Riva L, Cagliani R, Comi GP, Bresolin N, Giorda R, Pozzoli U. Silencer elements as possible inhibitors of pseudoexon splicing. Nucleic Acids Res 2009;32:1783-1791.
57. Zhang C, LiWH, Krainer AR, ZhangMQ. RNA landscape of evolution for optimal exon and intron discrimination. ProcNatl Acad Sci USA 2008;105:5797-5802.
58. Quiles F, Fernández-Rodríguez J, Mosca R, Feliubadaló L, Tornero E, Brunet J, Blanco I, Capellá G, Pujana M. A, Aloy P, Monteiro A, Lázaro C. Functional and structural analysis of Cterminal BRCA1 missense variants. PLoS One. 2013;17:1-6.
59. Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, Lu KH, Hortobagyi GN, Arun B. Accuracy of the BRCAPROmodel among women with bilateral breast cancer. Cancer 2009;115:725-730.
60. Balman J, Diez O, Rubio IT, Cardoso F. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22:31-34.
61. Vaz FH, Machado PM, Brandão RD, Laranjeira CT, Eugénio JS, Fernandes AH, André SP. Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additionalmethod in the selection of patients. J HistochemCytochem 2007;55:1105-1113.